McKesson Corporation $MCK Stock Holdings Increased by Rafferty Asset Management LLC

Rafferty Asset Management LLC raised its holdings in shares of McKesson Corporation (NYSE:MCK) by 4.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 13,807 shares of the company’s stock after purchasing an additional 583 shares during the quarter. Rafferty Asset Management LLC’s holdings in McKesson were worth $10,666,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. IAM Advisory LLC boosted its stake in shares of McKesson by 0.3% during the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after acquiring an additional 13 shares in the last quarter. PDS Planning Inc raised its position in shares of McKesson by 1.1% during the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after purchasing an additional 13 shares during the period. Berkshire Asset Management LLC PA lifted its holdings in shares of McKesson by 4.6% during the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after purchasing an additional 13 shares during the last quarter. Goldstein Advisors LLC boosted its position in shares of McKesson by 4.4% in the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after purchasing an additional 14 shares during the period. Finally, Warren Street Wealth Advisors LLC increased its stake in McKesson by 4.9% in the 3rd quarter. Warren Street Wealth Advisors LLC now owns 319 shares of the company’s stock worth $246,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Stock Performance

Shares of MCK opened at $984.61 on Monday. The company has a market capitalization of $120.60 billion, a PE ratio of 28.32, a PEG ratio of 1.59 and a beta of 0.38. The company’s 50 day moving average price is $868.77 and its 200 day moving average price is $807.56. McKesson Corporation has a 52 week low of $621.88 and a 52 week high of $987.37.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the prior year, the firm earned $8.03 EPS. The company’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Analyst Upgrades and Downgrades

A number of analysts have commented on MCK shares. Weiss Ratings lowered shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Morgan Stanley restated an “overweight” rating and set a $966.00 price target on shares of McKesson in a report on Thursday, January 29th. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Finally, Evercore restated an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a report on Thursday, November 6th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $943.50.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. The trade was a 5.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,143 shares of company stock worth $1,046,070. 0.08% of the stock is owned by company insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.